To investigate the anticancer activities of alkaloids from the Ba lotus seed (BLSA) in human nasopharyngeal carcinoma (NPC) CNE-1 cells, an MTT assay, flow cytometry, reverse transcription-polymerase chain reaction and western blotting were performed. BLSA was found to significantly reduce CNE-1 cell proliferation in a dose-dependent manner at all concentrations compared with the control (P<0.05). In addition, flow cytometry analysis identified that BLSA treatment significantly increased the sub-G1 content in CNE-1 cells (P<0.05). Following BLSA treatment, the mRNA and protein levels of a number of apoptosis-related factors, such as caspase family members (caspase-3, -8 and -9), B-cell lymphoma (Bcl)-2-associated X protein, Fas and Fas ligand were significantly increased compared with the control (P<0.05). This was accompanied by a significant decrease in anti-apoptotic Bcl-2 and Bcl-extra large protein expression compared with the control (P<0.05). Furthermore, BLSA treatment was determined to modulate CNE-1 cell expression of nuclear factor (NF)-κB and NF-κB inhibitor α. The results of the present study indicate that BLSA has anticancer activity through inducing cellular apoptosis. In addition, these results suggest that BLSA can be used as a therapeutic agent in NPC.
Introduction
Nasopharyngeal carcinoma (NPC) is a type of cancer with a high prevalence rate (2.8/100,000 and 1.9/100,000 people/year in men and women, respectively, in 2008) in Southeast China, particularly in the Guangxi, Guangdong, Hainan and the Hong Kong Special Administrative Region (1) . NPC is characterized by a high metastatic potential, frequent initial dissemination to regional lymph nodes and distant metastases, causing patients to succumb to NPC (2) . Early diagnosis of NPC and chemoradiotherapy treatment enables the best outcome. The overall five-year survival rate is associated with the NPC stage at diagnosis, ranging from between 58% at stage IV and 90% in stage I. However, in the advanced stages of NPC chemoradiotherapy is impractical (3, 4) . Therefore, the induction of NPC cell apoptosis is a strategy to control NPC and other malignancies in clinical therapy (5) .
B-cell lymphoma 2 (Bcl-2) is part of the Bcl-2 protein family, which regulates cell death by inducing or inhibiting apoptosis. The Bcl-2 family is divided into anti-apoptotic factors, including Bcl-2, Bcl-extra large (Bcl-xL) and Bcl-2-like protein 2, and pro-apoptotic factors, such as Bcl2-associated X protein (Bax), Bcl-2-associated death promoter, Bcl-2-interacting mediator of cell death (Bim), Bcl-2 homologous antagonist/killer and p53 upregulated modulator of apoptosis (6) . The extrinsic apoptosis signaling pathway is mediated by receptor-ligand binding. In this signaling pathway, the Fas receptor, Fas ligand (FasL), Fas-associated death domain (FADD) and caspase-8 mediate apoptosis. Alternatively, apoptotic stimuli can cause the depolarization of the inner mitochondrial membrane, leading to the release of cytochrome c (Cyt c) into the cytosol (7) . Cyt c molecules
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induce the activation of apoptotic protease activation factor-1 and procaspase-9. Activated caspase-8 and -9 cleave and activate the final executioner of apoptosis, caspase-3, resulting in chromatin condensation and DNA fragmentation (8) (9) (10) . The seed of Nelumbo nucifera (Gaertn), also known as the lotus, is traditionally used in Chinese folk medicine. A number of previous studies have reported that the lotus seed exhibits numerous health benefits and pharmacological effects, such as anti-ischemic (11), antioxidant (12) (13) (14) , hepatoprotective (12) , antiproliferative (15) (16) (17) (18) (19) , anti-inflammatory (20) , anti-infertility (21), anti-arrhythmic (22) (23) (24) (25) (26) , antifibrotic (27) and antiviral (28) activities. In the present study, the anticancer activity of alkaloids extracted from the Ba lotus seed (BLSA), a new variety of Nelumbo nucifera, which only grows in Chongqing, a city located in the southwest of China, was investigated in human NPC CNE-1 cells. In addition, the mechanism underlying this activity was examined.
Materials and methods
Chemical reagents. TRIzol, OligodT 18 primer, murine Maloney leukemia virus (MMLV) reverse transcriptase, RNase inhibitor, ethidium bromide (EtBr) and agarose were purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). All other chemical reagents were of analytical grade and purchased from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany).
Preparation of alkaloids from BLSA. Fresh BLSA was purchased from Chongqing Enterprise Engineering Research Center of Ba-lotus Breeding and Deep Processing (Chongqing, China), freeze-dried and ground into a fine powder. Alkaloids were extracted from powdered Ba louts seed (100 g) twice with 1,000 ml of ethanol (80% vol/vol) at 50˚C for 1 h. Following filtering, the extraction solution was loaded into a 80 cm cation exchange resin 732 column at 50˚C and the filtrate collected 3 h later. Distilled water was used to wash away water-soluble impurities and then an ethanol solution of BLSA extract (80%, v/v) at 3 ml/min was used to elute the alkaloids. The collected ethanol elucent was eluted by 80% ethanol solution (containing 2% of ammonia water) and finely condensed using a vacuum rotary evaporator at 37˚C, then freeze-dried and stored at -80˚C until required.
Cell culture. Human NPC CNE-1 cells were obtained from the Shanghai Institutes for Biological Sciences (Chinese Academy of Sciences, Shanghai, China). The cells were routinely maintained in Roswell Park Memorial Institute-1640 medium, supplemented with 10% (v/v) fetal bovine serum and 1% penicillin-streptomycin, at 37˚C in a humidified 5% CO 2 incubator at 95% relative humidity (model 3154; Forma Scientific, Inc., Marietta, OH, USA).
Cell viability assay. Cell viability was measured using the MTT assay. CNE-1 cells were seeded in 96-well plates (Nunc, Rochester, NY, USA) at a density of 1x10 4 cells/well. Following incubation for 24 h, cells were treated with a number of concentrations (50, 100 and 200 µg/ml) of BLSA for a further 24 h. Then, 0.5 mg/ml of MTT reagent (100 µl; Ekear, Shanghai, China; cat. no. M0105) was added to each well and the cells incubated for 4 h at 37˚C. The formazan crystals formed was dissolved in dimethyl sulfoxide (100 µl/well). Then, the absorbance of the wells at 540 nm was measured using a micro plate reader (model 680; Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Flow cytometry analysis. BLSA-treated CNE-1 cells were collected following digestion with trypsin, washed twice with cold phosphate buffered saline (PBS) and re-suspended in 2 ml PBS. Then, the DNA of BLSA-treated cells was stained with propidium iodide using a Cycletest Plus DNA Reagent Kit (BD Biosciences; Franklin Lakes, NJ, USA; cat. no. 340242), according to the manufacturer's protocol. Fluorescence intensity was determined using a FACSCalibur flow cytometer and the data analyzed using Cell Quest Pro software (version 5.2.1) (both BD Biosciences).
Reverse transcription polymerase chain reaction (RT-PCR).
RT-PCR was performed for the following genes: Caspase-3, -8 and -9, Bax, Bcl-2, Bcl-xL, Fas, FasL, NF-κB, IkB-α and GADPH. Total RNA was isolated from BLSA-treated CNE-1 cells using TRIzol reagent, according to the manufacturer's recommendations, and centrifuged at 12,000 x g for 15 min at 25˚C following the addition of chloroform. Isopropanol was added to the supernatant in a 1:1 ratio and the RNA pelleted by centrifugation (12,000 x g for 15 min at 4˚C). The RNA was washed with ethanol, solubilized in diethyl pyrocarbonate-treated RNase-free water and quantified by measuring the absorbance at 260 nm using a UV-1750 spectrophotometer (Shimadzu Corporation, Kyoto, Japan). RNA (1 µg) was reverse transcribed using a PCR master mix [1X reverse transcriptase buffer, dNTPs (1 mM), oligo(dT) 18 primers (500 ng), MMLV reverse transcriptase (140 units) and RNase inhibitor (40 units)] for 45 min at 42˚C. Then, cDNA (2 µl) was mixed with 1 µl of each primer (10 µM) and 16 µl of DNase-free water in a PCR premix tube (AccuPower PCR PreMix; Bioneer Corporation, Daejeon, Korea) and PCR was performed in an automatic thermocycler (Bioneer Corporation, Daejeon, South Korea) for 40 cycles of 94˚C for 5 min, 58˚C for 30 sec, and 72˚C for 90 sec, followed by a 10 min cycle at 95˚C. Sequences of the primers used in PCR are presented at Table I . The PCR products were separated on 2% agarose gels and visualized by EtBr staining. GAPDH was used for normalization of the results. Gene expression was quantified using ImageJ software (version 1.44; National Institutes of Health, Bethesda, MD, USA) and results presented as fold change compared to the control group.
Protein extraction and western blot analysis. For protein extraction, BLSA-treated CNE-1 cells were washed with ice-cold PBS, homogenized with ice-cold radioimmunoprecipitation assay (RIPA) buffer and centrifuged at 13,000 x g for 30 min at 4˚C. Protein concentrations were determined using the Bradford Protein Assay kit (Bio-Rad Laboratories, Inc.; cat. no. 5000001). For Western blot analysis, 30 µg of protein extract was separated by SDS-PAGE (10% gel) and then electrotransferred onto a nitrocellulose membrane (Schleicher & Schuell Bioscience, Inc., Keene, NH, USA). Blocking and antibody treatment were conducted in 10% skimmed milk for 2 h at 4˚C. The blots were incubated for 4 h at 4˚C with primary antibodies against caspase-3 (rabbit monoclonal; 1:1,000; cat. no. 14220S), caspase-8 (rabbit monoclonal; 1:1,000; cat. no. 9478S) and caspase-9 (rabbit monoclonal; 1:1,000; cat. no. 9508S), and Bax (rabbit monoclonal; 1:1,000; cat. no. 14796S), Bcl-2 (rabbit monoclonal; 1:1,000; cat. no. 4223S), Bcl-xL (rabbit monoclonal; 1:1,000; cat. no. 2764S), Fas (mouse monoclonal; 1:1,000; cat. no. 8023S), FasL (rabbit polyclonal; 1:1,000; cat. no. 4273S), NF-κB (mouse monoclonal; 1:1,000; cat. no. 13681S), IκB-α (rabbit monoclonal; 1:1,000; cat. no. 4812S) and β-actin (mouse monoclonal; 1:1,000; cat. no. 12262S) (all Cell Signaling Technology, Inc., Danvers, MA, USA). Following washing with PBS containing 0.05% Tween 20 (PBS-T), the blots were incubated with horseradish peroxidase-conjugated goat anti-rabbit (cat. no. 7074S) or horse anti-mouse antibodies (cat. no. 7076S) at a dilution of 1:5,000 (both Cell Signaling Technology, Inc.) for 1 h at room temperature. Then, blots were washed three times with PBS-T and antibody binding visualized by enhanced chemiluminescence (ECL Western Blotting Detection kit; GE Healthcare Life Sciences, Little Chalfont, UK; cat. no. RPN2108). Protein expression was quantified using ImageJ software (version 1.44; National Institutes of Health).
Statistical analysis.
Results are presented as the mean ± standard deviation. Differences between the mean values of groups were assessed by one-way analysis of the variance, followed by a post-hoc Duncan's new multiple range test. P<0.05 was considered to indicate a statistically significant difference.
SAS software (version 9.1; SAS Institute, Inc., Cary, NC, USA) was used for statistical analysis.
Results
BLSA decreases CNE-1 cell proliferation. BLSA was found to significantly reduce CNE-1 cell proliferation in vitro, in a dose-dependent manner, at all concentrations tested compared with the control group (P<0.05; Table II ). The highest dose of BLSA (200 µg/ml) showed the greatest inhibitory activity (81.3±0.2%; Table II ). RT-PCR, reverse transcription polymerase chain reaction; Bax, Bcl2-associated X protein; Bcl-2, B-cell lymphoma 2; Bcl-xL, Bcl-extra large; FasL, Fas ligand; NF-κB, nuclear factor-κB; IκB-α, nuclear factor-κB inhibitor α. 
BLSA induces apoptosis in CNE-1 cells.
Flow cytometry analysis identified that BLSA increased apoptosis in CNE-1 cells in a dose-dependent manner. BLSA treatment (50, 100 and 200 µg/ml) significantly increased the sub-G1 DNA content of CNE-1 cells to 7.1 (P<0.05), 17.8 (P<0.01) and 38.9% (P<0.01), respectively, compared with 2.6% in the untreated control group (Fig. 1) .
BLSA increases Fas and FasL protein expression in CNE-1 cells.
The effect of BLSA on mRNA and protein levels of specific genes was determined by RT-PCR and western blot analysis, respectively. BLSA treatment was identified to significantly increase mRNA and protein levels of Fas and FasL in CNE-1 cells, in a dose-dependent manner, at all concentrations tested compared with the control (P<0.05; Fig. 2 ). The highest dose of BLSA (200 µg/ml) significantly up-regulated Fas (2.9 fold) and FasL (1.7 fold) mRNA levels, and Fas (1.5 fold) and FasL (3.3 fold) protein levels compared with the control group (all P<0.01; Fig. 2C and D) .
BLSA increases caspase-3, -8 and -9 expression in CNE-1 cells.
BLSA treatment significantly increased mRNA and protein expression levels of caspase-3, -8 and -9 in CNE-1 cells, at all concentrations tested compared with the control (P<0.05; Fig. 3 ). The highest dose of BLSA (200 µg/ml) significantly increased mRNA and protein levels of caspase-3 (26.7 and 1.4 fold, respectively; Fig. 3C ), -8 (3.3 and 1.5 fold, respectively; Fig. 3D ) and -9 (5.3 and 1.6 fold, respectively; Fig. 3E ) compared with the untreated control group (all P<0.01).
BLSA modulates Bcl-2, Bcl-xL and Bax expression in CNE-1 cells.
Compared with the control group, BLSA treatment significantly decreased expression of Bcl-2 and Bcl-xL mRNA and protein, and increased expression of Bax mRNA and protein, in a dose dependent manner, in CNE-1 cells, at all concentrations tested (P<0.05; Fig. 4 ). At the highest dose (200 µg/ml), BLSA significantly reduced mRNA and protein levels of Bcl-2 (90 and 94%, respectively) and Bcl-xL (81 and 75%, respectively) compared with the control group (P<0.01; Fig. 4D and E). In contrast, 200 µg/ml BLSA enhanced mRNA (10.6 fold; P<0.01) and protein (1.6 fold; P<0.05) levels of Bax in CNE-1 cells (Fig. 4C) .
BLSA modulates NF-κB and IκB-α expression in CNE-1 cells.
BLSA treatment significantly decreased NF-κB mRNA and protein expression, and increased IκB-α mRNA and protein expression, in a dose dependent manner in CNE-1 cells, at all concentrations tested (P<0.05 vs. the control group; Fig. 5 ). Following treatment with 200 µg/ml BLSA, NF-κB mRNA and protein levels were significantly decreased by 78% and 35%, respectively, compared with the control group (P<0.01; Fig. 5C ). In addition, BLSA increased mRNA and protein levels of IκB-α by 32.7 and 2.3-fold, respectively, compared with the control group (P<0.01; Fig. 5D ).
Discussion
Alkaloids, isolated from herbs, may possess anti-cancer activities, including induction of cell cycle arrest, apoptosis, autophagy, and inhibition of angiogenesis and metastasis (29) . A recent study reported that a number of alkaloids isolated from N. nucifera Gaertn. cv. Rosa-plena exhibited antioxidant and anticancer activity in vitro (30) . In the present study, BLSA exhibited anti-cancer effects, associated with the induction of apoptosis, in CNE-1 cells. BLSA significantly reduced CNE-1 cell proliferation and promoted transition into the sub-G1 phase. These results indicate that the anti-CNE-1 effects of BLSA are associated with apoptosis.
In the current study, mRNA and proteins expression levels of a number of apoptosis-associated genes in BLSA-treated CNE-1 cells were investigated using RT-PCR and western blotting, respectively. Following treatment for 24 h with BLSA, mRNA and protein levels of Fas and FasL were significantly increased compared with untreated cells. Fas and FasL are inducers of apoptosis that serve a primary role in death receptor-mediated apoptosis (31) . Activation of Fas/FasL recruits FADD and the death domain, which subsequently induce the activation of caspase-8, -9 and -10, key regulators that promote cellar apoptosis (32) .
The results of the present study determined that mRNA and protein levels of caspase-3, -8 and -9 were significantly increased in BLSA-treated CNE-1 cells compared with the control group. The caspase signaling cascade is a key event in extrinsic and intrinsic apoptosis, which is characterized by the activation of caspase-8 and -9, respectively (9). Caspase-8, the initiator caspase in Fas signaling, is recruited to the acti- Figure 3 . Effect of alkaloids of BLSA on the (A) mRNA and (B) protein expression levels of caspase-3, -8 and -9 in human NPC CNE-1 cells. Fold change of (C) caspase-3, (D) caspase-8 and (E) caspase-9 mRNA and protein expression over the control. Fold change over the control for mRNA was calculated as mRNA expression/GAPDH expression. Fold change over the control for protein was calculated as protein expression/β-actin expression. Results are presented as the mean ± the standard deviation of triplicate experiments. Differences between groups were statically analyzed using Duncan's new multiple-range test. vated Fas receptor and facilitates death receptor-mediated apoptosis (33) . Caspase-9, an apoptotic effector molecule in intrinsic apoptosis, initiates programmed cell death following activation (10) . Activated caspase-8 and -9 activate caspase-3, an executioner caspase that subsequently induces apoptosis (8) .
These results indicate that BLSA induces CNE-1 cell apoptosis through activating extrinsic (Fas/FasL) and intrinsic apoptotic signaling pathways.
The Bcl-2 family, a well-known family of apoptosis regulators, serves a primary role in intrinsic apoptosis (34) . Bcl-2 and Bcl-xL are typically anti-apoptotic factors that block the release of Cyt c from mitochondria and thus promote cell survival. Bcl-2 can reduce the release of Cyt c from the mitochondria, thus inhibiting apoptosis (6) . In contrast, Bax is a pro-apoptotic factor that promotes apoptosis (6, 7) . The balance between antiand pro-apoptotic factors influences the occurrence of apoptosis, and is associated with the success rate of chemotherapy in cancer patients (35) . In the present study, BLSA treatment significantly increased mRNA and protein levels of pro-apoptotic Bax, and reduced mRNA and protein levels of anti-apoptotic Bcl-2 and Bcl-xL in CNE-1 cells. Activated Bax is directly engaged by Bim to promote apoptosis (36) . In addition, caspases-8 may activate Bax and induce the release of Cyt c from the mitochondria, causing the cleavage of caspase-9 and contributing to the activation of caspase-3 (6, 37) . The results of the current study suggest that BLSA modulates the ratio of anti-apoptotic to pro-apoptotic factors, in particular by enhancing the expression Bax to promote the apoptosis of CNE-1 cells.
NF-κB reduces tumor necrosis factor (TNF)-α-induced cell apoptosis (38) and is an important negative regulator of apoptosis in cancer cells (39) . Deregulation of NF-κB expression has been found in a number of human cancers (40, 41) . Overexpression of NF-κB promotes cell proliferation and reduces cell death (42) . In addition, NF-κB can directly activate Bcl-xL (43) and suppress a number of anti-apoptotic factors, such as inhibitor of apoptosis, caspase-8-like FADD-like interleukin-1β-converting enzyme inhibitory protein, TNF receptor associated factor 1 (TRAF1) and TRAF2, to regulate apoptosis (44) . Following treatment with BLSA, mRNA and protein levels of NF-κB were significantly reduced in CNE-1 cells. In addition, BLSA treatment significantly increased mRNA and protein levels of IκB-α. Increasing IκB-α levels is a therapeutic strategy to reduce cancer cell growth in clinical chemotherapy (45) (46) (47) .
In conclusion, the results of the present study indicate that BLSA suppresses the proliferation of human CNE-1 NPC cells in vitro. In addition, the results indicate that BLSA induces apoptosis, through reducing the ratio of anti-apoptotic (Bcl-2 and Bcl-xL) to pro-apoptotic (Bax) factors, increasing mRNA and protein expression levels of Fas/FasL and promoting cleavage of caspase-3, -8 and -9 in CNE-1 cells. BLSA, as an inducer of apoptosis, may have future applications as an adjuvant in clinical therapy for NPC patients.
